ZOLOFT

Compare ZOLOFT  to:
Compare
Compare

Generic Name for ZOLOFT

Sertraline (as HCl) 25mg, 50mg, 100mg; scored tabs.

Legal Classification:

Rx

Pharmacological Class for ZOLOFT

SSRI.

Manufacturer of ZOLOFT

Pfizer Labs

Indications for ZOLOFT

Depression. Premenstrual dysphoric disorder (PMDD).

Adult dose for ZOLOFT

Give once daily (AM or PM). Depression: initially 50mg/day, may increase at 1-week intervals; max 200mg/day. PMDD: give either for entire menstrual cycle or only during luteal phase. Luteal phase dosing: initially 50mg/day; if no response, may increase to 100mg/day, starting each cycle at 50mg/day for 3 days. Entire cycle dosing: initially 50mg/day, if no response, may increase by 50mg/cycle to max 150mg/day.

Children's dosing for ZOLOFT

Not recommended.

Also:

Contraindications for ZOLOFT

During or within 14 days of MAOIs. Concomitant pimozide. Oral soln: concomitant disulfiram.

Warnings/Precautions for ZOLOFT

Monitor for mania/hypomania. Seizure disorders. Suicidal tendencies. Hepatic dysfunction (reduce dose or prolong dosing interval). Cardiac disease. Conditions that affect metabolism or hemodynamic response. Volume depleted. Reevaluate periodically in long-term use. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.

Interactions for ZOLOFT

See Contraindications. Avoid alcohol. May potentiate or be potentiated by cimetidine, protein bound drugs (eg, warfarin, digitoxin). Caution with other CNS drugs and drugs metabolized by CYP2D6 (eg, tricyclics, flecainide, propafenone). Potentiates diazepam, tolbutamide. Monitor lithium, warfarin, tricyclics. Monitor patients on sumatriptan for serotonin syndrome (eg, weakness, incoordination, hyperreflexia).

Adverse Reactions for ZOLOFT

GI upset, insomnia, somnolence, sexual dysfunction, tremor, dry mouth, sweating, anorexia, weight loss, anxiety, decreased libido, hyponatremia, weak uricosuric effect.

How is ZOLOFT supplied?

Tabs 25mg—50
50mg, 100mg—100, 500
Conc—60mL (w. dropper)

Related Disease:

Depression
Premenstrual dysphoric disorder

Related Resources

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions